Wyeth takes another look at antibody pact

In yet another sign of monoclonal antibodies' popularity among big drug developers, Wyeth has extend its evaluation of selected Raven Biotechnologies MAb antibodies. Raven, which signed a pact with Wyeth earlier this year, will receive an undisclosed milestone payment.

2007 hasn't been a pretty year for Wyeth. A string of woeful developments has left the company stripped of three of its leading drug candidates, and the drug developer could certainly use MAb technology to revive its pipeline. A new Datamonitor report projects 14 percent annual growth in the market for the antibody drugs, which mimic the body's own immune system. Raven was a 2003 Fierce 15 company.

- see this release for more

ALSO: Take a look at Wyeth's pipeline. Report

Related Articles:
MAbs are hottest segment of biotech industry. Report
New venture round boosts Raven's cancer work. Report